Home/Pipeline/Selective FLT3 Inhibitors

Selective FLT3 Inhibitors

Acute Myeloid Leukemia (AML)

Pre-clinicalActive

Key Facts

Indication

Acute Myeloid Leukemia (AML)

Phase

Pre-clinical

Status

Active

Company

Vichem Chemie Research

About Vichem Chemie Research

Vichem Chemie Research is a Budapest-based, private contract research organization (CRO) and drug discovery company with a 30+ year history. Its core business model combines fee-for-service chemistry and biology work with the development of its own proprietary chemical libraries and internal therapeutic programs, primarily focused on kinase inhibitors. The company leverages strategic alliances and has received grant funding from Hungarian and European sources, indicating a hybrid revenue model of services and grants while advancing its pipeline.

View full company profile

Therapeutic Areas

Oncology Virology

Other Acute Myeloid Leukemia (AML) Drugs

Drug	Company	Phase	Status
Mipletamig (APVO436)	Aptevo Therapeutics	Phase 1/2	Active
lomonitinib	Lomond Therapeutics	IND-Enabling	Active
lonitoclax	Lomond Therapeutics	Phase 1	Active
Menin Inhibitor	Lomond Therapeutics	Discovery	Active
AB8939	AB Science	Phase 1	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
ADI-PEG 20 (pegargiminase)	Polaris Pharma	Phase 1	Active
NC525	NextCure	Preclinical	Active
ACD-101	Advanced Cellular Dynamics	Phase 1	IND-Enabling
ABD-3001	Advanced Biodesign	Phase 1	Active (trial began early 2023)
HC-7366	HiberCell	Phase 1b	Active - Monotherapy & in combination with venetoclax and azacitidine
Prexigebersen (BP1001)	Bio-Path Holdings	Phase 2	Active